title: Naturally circulating dendritic cells to vaccinate cancer patients.
abstract: Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.
authors.affiliation: Department of Tumor Immunology; Nijmegen Centre for Molecular Life Sciences; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands ; Department of Medical Oncology; Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands.
authors.forename: Kalijn F
authors.initials: KF
authors.lastname: Bol
authors.forename: Jurjen
authors.initials: J
authors.lastname: Tel
authors.forename: I Jolanda M
authors.initials: IJ
authors.lastname: de Vries
authors.forename: Carl G
authors.initials: CG
authors.lastname: Figdor
keywords: cancer immunotherapy; dendritic-cell targeting; dendritic-cell vaccination; myeloid dendritic cells; plasmacytoid dendritic cells